NSK-SD纳豆激酶在心血管疾病高危人群中应用疗效的临床研究

中华养生保健 ›› 2024, Vol. 42 ›› Issue (5): 8-11.

NSK-SD纳豆激酶在心血管疾病高危人群中应用疗效的临床研究

钱申贤¹, 李佩璋², 陈宁^3,*, 朱平⁴, 安奇⁴, 赵晓燕⁵, 张瑞芳⁶, 胡卫红⁵, 刘小明⁵, 吴炳南⁷

1.杭州市第一人民医院血液科,浙江杭州,310000;
2.杭州市第一人民医院心内科,浙江杭州,310000;
3.杭州市第一人民医院老年医学科,浙江杭州,310000;
4.杭州市第一人民医院全科医疗科,浙江杭州,310000;
5.杭州市第一人民医院神经外科,浙江杭州,310000;
6.杭州市第一人民医院普通内科,浙江杭州,310000;
7.日生研生命科学（浙江）有限公司,浙江杭州,310000

出版日期:2024-03-01 发布日期:2024-02-27
通讯作者: ^*陈宁,E-mail：13023612300@163.com。
作者简介:钱申贤（1962—）,男,汉族,籍贯：浙江省杭州市,硕士研究生,主任医师,研究方向：血液病、淋巴结瘤和多发性骨髓瘤的临床和实验研究。

NSK-SD Nattokinase in the Treatment of Cardiovascular and Cerebrovascular High Risk Population

QIAN Shen-xian¹, LI Pei-zhang², CHEN Ning^3,*, ZHU Ping⁴, AN Qi⁴, ZHAO Xiao-yan⁵, ZHANG Rui-fang⁶, HU Wei-hong⁵, LIU Xiao-ming⁵, WU Bing-nan⁷

1. Department of Hematology, Hangzhou First People's Hospital, Hangzhou Zhejiang 310000, China;
2. Department of Cardiology, Hangzhou First People's Hospital, Hangzhou Zhejiang 310000, China;
3. Department of Geriatrics, Hangzhou First People's Hospital, Hangzhou Zhejiang 310000, China;
4. Department of General Medicine, Hangzhou First People's Hospital, Hangzhou Zhejiang 310000, China;
5. Department of Neurosurgery, Hangzhou First People's Hospital, Hangzhou Zhejiang 310000, China;
6. Department of General Internal Medicine, Hangzhou First People's Hospital, Hangzhou Zhejiang 310000, China;
7. Rishengyan Life Sciences (Zhejiang) Co., Ltd., Hangzhou Zhejiang 310000, China

Online:2024-03-01 Published:2024-02-27

摘要/Abstract

摘要： 目的评估纳豆激酶在心血管疾病高危人群中应用疗效。方法纳豆激酶临床研究课题组选取2021年1月—2022年12月浙江大学医学院附属杭州市第一人民医院收治的97例心血管高危患者为研究对象,在90 d的研究期间服用8 000 FU/d纳豆激酶（NSK-SD）,分别在基线、第30天和第90天进行采血,检测血脂、凝血四项、血小板聚集率和D-二聚体水平,在基线和第90天进行TCD检测和颈动脉彩超。结果 97例患者全部完成了这项研究,依从性良好。服用纳豆激酶30 d后血浆黏度显著下降（P<0.05）;服用纳豆激酶90 d,ADP血小板聚集率300 s、ADP血小板最大聚集率、D-二聚体、全血低切黏度（5/s）、全血黏度（50/s）和全血高切黏度（200/s）显著下降（P<0.05）;此外,全血低切黏度1/s在服用30 d和90 d后均显著下降（P<0.05）。影像学检查显示,大脑血流速度和流速差异常患者改善率分别为71.4%和87.5%;颈动脉内斑块和中膜增厚的改善比例分别为46.7%和42.1%。结论纳豆激酶可以显著改善心血管疾病高危人群的ADP血小板聚集率300 s、ADP血小板最大聚集率和全血黏度,且疗效与治疗时间呈正相关。服用纳豆激酶90 d后的影像学检查发现患者的大脑供血得到明显改善,颈动脉粥样硬化进展也得到了明显的抑制。这表明纳豆激酶对心脑血管疾病的防治有较为显著的作用。

关键词: 纳豆激酶, 心脑血管疾病, 疗效, 临床试验

Abstract: Objective Nattokinase, a fermented soybean extract, has recently been shown to reduce the risk of cardiovascular and cerebrovascular disease. The purpose of this study was to evaluate the efficacy of nattokinase in the cardiovascular and cerebrovascular high-risk population in China. Methods A total of 97 cardiovascular and cerebrovascular high-risk subjects received 8000 FU nattokinase (NSK-SD) daily during the 90-day study period, and blood samples were taken at baseline, on day 30 and day 90, respectively, to detect lipids, clotting, platelet aggregation rate and D-dimer. TCD testing and carotid ultrasound were performed at baseline and day 90. Results All 97 people completed the study with good compliance. After 30 days of nattokinase treatment, plasma viscosity decreased significantly (P<0.05). After taking nattokinase for 90 days, ADP platelet aggregation rate was 300 s, maximum ADP platelet aggregation rate, D-dimer, whole blood low shear viscosity 5/s, whole blood viscosity 50/s and whole blood high shear viscosity 200/s (P<0.05). In addition, whole blood low shear viscosity 1/s decreased significantly after 30 days and 90 days of administration (P<0.05). The improvement rate of patients with different blood flow velocity and flow velocity was 71.4% and 87.5%, respectively. The improvement rates of carotid plaque and media thickening were 46.7% and 42.1%, respectively. Conclusion The intake of nattokinase in the Chinese population was significantly correlated with the improvement of platelet function, D-dimer and whole blood viscosity in the high-risk population of cardiovascular and cerebrovascular diseases, and the effect was more obvious with the extension of time, indicating that nattokinase has a significant effect on the prevention and treatment of cardiovascular and cerebrovascular diseases.

Key words: nattokinase, cardiovascular and cerebrovascular diseases, curative effect, clinical trials

中图分类号:

钱申贤, 李佩璋, 陈宁, 朱平, 安奇, 赵晓燕, 张瑞芳, 胡卫红, 刘小明, 吴炳南. NSK-SD纳豆激酶在心血管疾病高危人群中应用疗效的临床研究[J]. 中华养生保健, 2024, 42(5): 8-11.

QIAN Shen-xian, LI Pei-zhang, CHEN Ning, ZHU Ping, AN Qi, ZHAO Xiao-yan, ZHANG Rui-fang, HU Wei-hong, LIU Xiao-ming, WU Bing-nan. NSK-SD Nattokinase in the Treatment of Cardiovascular and Cerebrovascular High Risk Population[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(5): 8-11.

参考文献

[1] GERAGHTY L, FIGTREE G A, SCHUTTE A E, et al.Cardiovascular Disease in Women: From Pathophysiology to Novel and Emerging Risk Factors[J]. Heart Lung Circ,2021,30(1):9-17.
[2] NOZUE M, SHIMAZU T, CHARVAT H, et al.Fermented soy products intake and risk of cardiovascular disease and total cancer incidence: The Japan Public Health Center-based Prospective study[J]. Eur J Clin Nutr,2021, 75(6):954-968.
[3] YAN Z, ZHANG X, LI C, et al.Association between consumption of soy and risk of cardiovascular disease: A meta-analysis of observational studies[J]. Eur J Prev Cardiol,2017,24(7):735-747.
[4] PENG Y, YANG X, ZHANG Y.Microbial fibrinolytic enzymes: an overview of source, production, properties, and thrombolytic activity in vivo[J]. Appl Microbiol Biotechnol,2005,69(2):126-132.
[5] CHEN H, MCGOWAN E M, REN N, et al.Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases[J]. Biomark Insights,2018:13.
[6] KRISHNAMURTHY A, BELUR P D.A novel fibrinolytic serine metalloprotease from the marine Serratia marcescens subsp. sakuensis: Purification and characterization[J]. Int J Biol Macromol,2018,112:110-118.
[7] GUO H, BAN Y H, CHA Y, et al.Comparative anti-thrombotic activity and haemorrhagic adverse effect of nattokinase and tissue-type plasminogen activator[J]. Food Sci Biotechnol,2019,28(5):1535-1542.
[8] HSIA C H, SHEN M C, LIN J S, et al.Nattokinase decreases plasma levels of fibrinogen, factor VⅡ, and factor V Ⅲ in human subjects[J]. Nutr Res, 2009,29(3):190-196.
[9] KUROSAWA Y, NIRENGI S, HOMMA T, et al.A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles[J]. Sci Rep, 2015, 5:11601.
[10] REN N N, CHEN H J, LI Y, et al.A clinical study on the effect of nattokinase on carotid artery atherosclerosis and hyperlipidaemia[J]. Zhonghua Yi Xue Za Zhi,2017,97(26):2038-2042.
[11] KEZIAH S M, DEVI C S.Fibrinolytic and ACE Inhibitory Activity of Nattokinase Extracted from Bacillus subtilis VITMS 2: A Strain Isolated from Fermented Milk of Vigna unguiculata[J]. Protein J,2021,40(6): 876-890.
[12] JENSEN G S, LENNINGER M, ERO M P, et al.Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial[J]. Integr Blood Press Control,2016,9:95-104.
[13] KIM J Y, GUM S N, PAIK J K, et al.Effects of nattokinase on bloodpressure: a randomized,controlled trial[J]. Hypertens Res,2008,31(8):1583-1588.
[14] BHATT P C, PATHAK S, KUMAR V, et al.Attenuation of neurobehavioral and neurochemical abnormalities in animal model of cognitive deficits of Alzheimer’s disease by fermented soybean nanonutraceutical[J]. Inflammopharmacology,2018,26(1):105-118.

[1]	孙涛, 蔡珂, 刘姿杉, 周春丽, 孙龙军. 金丹排石汤治疗湿热型输尿管结石的临床效果[J]. 中华养生保健, 2024, 42(9): 12-16.
[2]	张立伟, 王颖, 李懿娇, 徐金婵. 埋针联合耳穴压豆辅助治疗慢阻肺疾病痰浊阻肺证患者的疗效观察[J]. 中华养生保健, 2024, 42(9): 21-24.
[3]	覃桂水, 陶怡, 郑美华. “以通为用”指导下不同刮痧方法在气滞血瘀型肩周炎患者中的临床应用[J]. 中华养生保健, 2024, 42(9): 31-34.
[4]	李伟. 中医药透配合针灸治疗老年性膝关节骨性关节炎的临床观察[J]. 中华养生保健, 2024, 42(9): 34-37.
[5]	杨楠. 滋阴清热汤治疗月经不调的临床疗效及对血清激素水平的影响研究[J]. 中华养生保健, 2024, 42(9): 37-39.
[6]	孙欢欢. 依达拉奉联合阿托伐他汀治疗脑梗死恢复期患者的相关研究[J]. 中华养生保健, 2024, 42(9): 187-190.
[7]	叶枫, 王甜, 符冬梅, 蔡怡欢, 伍娟, 曾奕. 中国临床试验注册中心轻度认知障碍相关临床试验的特征分析[J]. 中华养生保健, 2024, 42(8): 4-5.
[8]	李晓琳, 李斯文, 冯妮. 四君子汤联合替吉奥治疗晚期胃癌患者的临床疗效及安全性分析[J]. 中华养生保健, 2024, 42(8): 24-27.
[9]	喻霞, 齐慧丽, 张春红. 紫杉醇注射液联合卡铂治疗卵巢癌对患者免疫功能的影响[J]. 中华养生保健, 2024, 42(8): 40-44.
[10]	马周宇. 非锁定钢板内固定术和锁定钢板内固定术治疗跟骨粉碎性骨折的临床效果比较研究[J]. 中华养生保健, 2024, 42(8): 174-177.
[11]	杨廷智, 马平, 付有娟, 罗兵, 何文清. 敷膝热奄包联合推拿治疗膝关节炎的临床疗效观察[J]. 中华养生保健, 2024, 42(7): 1-4.
[12]	邵光辉. 云南白药胶囊辅助经皮微创内固定术对胫骨平台骨折患者愈合的影响[J]. 中华养生保健, 2024, 42(7): 23-26.
[13]	闵晶晶, 杜林栋, 聂成梅. 益肾扶阳粉隔药灸法对肾病综合征水肿的治疗效果观察[J]. 中华养生保健, 2024, 42(6): 1-4.
[14]	张建忠, 任明媛, 王鑫, 徐艳艳, 李小静, 苗国英, 王利涛. 微针联合卤米松乳膏及白灵片治疗肢端白癜风效果分析[J]. 中华养生保健, 2024, 42(6): 9-12.
[15]	俞生, 田仁丹. 熏洗法辅助针灸及康复训练法对中风后遗症临床疗效的影响研究[J]. 中华养生保健, 2024, 42(6): 34-37.